High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 485-491

  Henderson, Ying C ^a   Shellenberger, Thomas D ^a   Williams, Michelle D ^b   El Naggar, Adel K ^b   Fredrick, Mitchell J ^a   Cieply, Kathleen M ^d   Clayman, Gary L ^a,c  

^a Department of Head and Neck Surgery ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; PROTEIN PATCHED; PROTEIN RET;

ADULT; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA;

ADULT; BASE SEQUENCE; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECURRENCE; THYROID NEOPLASMS;

EID: 59449089240     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0933     Document Type: Article

References (48)

1. Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am 1995:24:711 -60.
2. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375-81; discussion 81 -4.
3. Ortiz S, Rodriguez JM, Parrilla P, et al. Recurrent papillary thyroid cancer: analysis of prognostic factors including the histological variant. Eur J Surg 2001;167:406-12.
4. Robbins J, Merino MJ, Boice JD, Jr., et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991;115:133-47.
5. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62.
6. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-85.
7. Wojciechowska K, Lewinski A. BRAF mutations in papillary thyroid carcinoma. Endocr Regul 2006;40: 129-38.
8. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92: 4085-90.
9. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90: 6373-9.
10. Puxeddu E, Moretti S. Clinical prognosis in BRAF- mutated PTC. Arq Bras Endocrinol Metabol 2007;51: 736-47.
11. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 2000;19:5590-7.
12. Jhiang SM, Mazzaferri EL The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 1994;123: 331-7.
13. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998;4:287-94.
14. Nakazawa T, Kondo T Kobayashi Y, et al. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer 2005;104:943-51.
15. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 2000;85:1170-5.
16. Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 2001;86:3211-6.
17. Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-4.
18. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
19. Bongarzone I, Monzini N, Borrello MG, et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit Rlα of cyclic AMP-dependent protein kinase A. Mol Cell Biol 1993; 13:358-66.
20. Santoro M, Dathan NA, Berlingieri MT et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994;9:509-16.
21. Beimfohr C, Klugbauer S, Demidchik EP, et al. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int J Cancer 1999;80:842-7.
22. Brzezianska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Wloch J, Lewinski A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res 2006;599:26-35.
23. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-40.
24. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA micro- array analysis. Oncogene 2005;24:6646-56.
25. Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB, Asa SL. Oncogene profile of papillary thyroid carcinoma. Surgery 1999;125:46-52.
26. Naito H, Pairojkul C, Kitahori Y, et al. Different ras gene mutational frequencies in thyroid papillary carcinomas in Japan andThailand. Cancer Lett 1998:131:171 -5.
27. Hedinger C, Williams ED, Sobin LH, Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer1989;63:908-11.
28. Rosai J, Carcangiu ML, Delellis RA. Tumors of the Thyroid Gland. Atlas of tumor pathology, third series; fasc 5: Armed Forces Institute of Pathology, Washington (DC); 1992. p. 65-122.
29. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
30. Di Cristofaro J, Marcy M, Vasko V, et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 2006;37:824-30.
31. Chua EL, Wu WM, Tran KT, et al. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J Clin Endocrinol Metab 2000;85:2733-9.
32. Nakayama H, Yoshida A, Nakamura Y, et al. Clinical significance of BRAF (V600E) mutation and Ki- 67 labeling index in papillary thyroid carcinomas. Anticancer Res 2007;27:3645 - 9.
33. Grigsby PW, Baglan K, Siegel BA. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 1999;85:945-51.
34. Biscolla RP, Cerutti JM, Maciel RM. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood. J Clin Endocrinol Metab 2000;85:3623-7.
35. Brzezianska E, Pastuszak-Lewandoska D, Wojciechowska K, et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett 2007;28:351 -9.
36. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-70.
37. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
38. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
39. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83-95.
40. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21 Suppl 2:S37-43.
41. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006;91:3603-10.
42. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-20.
43. Ciampi R. Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinol 2007;148:936-41.
44. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-80.
45. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003:63:4561 -7.
46. Wright PA, Lemoine NR, Mayall ES, et al. Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br J Cancer 1989;60: 576-7.
47. Fagin JA. Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 2004;89:4264-6.
48. Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 2000;128: 984-93.